Matteo Tozzi, MD, vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD, PhD, professor emeritus of vascular surgery at the University Medical Center Utrecht in The Netherlands, provided insights on the progress of the aXess trial in an [...]
Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support Xeltis’ [...]
Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of a European first-in-human trial to [...]
The Xeltis Executive Team has been joined by seasoned medtech business leader David Mester as Vice-President, Business Lead, Valve. David has over 30 years of experience in structural heart devices and dedicated his career to advancing innovative materials and [...]
Xeltis hired Alexander Goemans as Chief Financial Officer. Alexander brings significant experience in strategy consulting, investment management and financial management during which he completed several acquisitions, equity raises and financings. Prior to joining Xeltis, Alexander served as CFO of [...]
To learn how Xeltis’ restorative hemodialysis access graft, aXess, may be opening new horizons for patients with kidney failure, tune in the Visionary Endovascular and Vascular Education (VERVE) Symposium in Sidney, up to 4 December. In his talk on Saturday [...]
The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will support the acceleration of clinical programmes for three of Xeltis’ revolutionary, restorative devices. The financing is being made available [...]
Xeltis announced today that is planning to accelerate its clinical trial program for three restorative devices in parallel. CEO Eliane Schutte provided a sneak preview on Xeltis' plans to an audience of investors and medtech companies at the Medtech [...]
Leading global research institutions will be presenting results from joint research on Xeltis restorative devices at TERMIS 6th World Congress in Maastricht 15-18 November. Organised by the Tissue Engineering and Regenerative Medicine International Society, the congress will focus on [...]
The XABG restorative coronary artery bypass graft (CABG) by Xeltis will feature in a session on the future of vascular therapeutic at the European Symposium on Vascular Biomaterials (ESVB) meeting. In his presentation “Xeltis: towards grafts from supramolecular materials”, [...]
